Later-line treatment strategies in metastatic colorectal cancer (mCRC)

In this interactive patient case, we will consider later-line treatment strategies for a patient with advanced metastatic colorectal cancer (CRC). You will meet a 61-year-old man whose colorectal cancer has progressed following treatment with chemotherapy and a monoclonal antibody. 

As you work through the case, you will be asked to make decisions on his treatment as he progresses through to 2^nd- and 3^rd-line and beyond. Supporting information is provided along the way to help your decision-making process. 

This interactive patient case will deepen your understanding of: 

• Treatment options for advanced mCRC patients in later line 
• The optimal sequence of these treatments to ensure patients benefit from all available treatments
• Considerations for rechallenge or reintroduction of prior therapies

Clinical takeaways 

• Treatment of advanced CRC should be considered as a continuum of care 
• Patients should receive treatment with as many therapeutic options as are available 
• Recommended treatments in the third-line setting include: regorafenib, TAS-102 + bevacizumab, anti-EGFR in RAS and BRAF wild-type patients not previously treated with EGFR antibodies 
• It is important to use all available therapeutics and to sequence treatments based on patient characteristics and molecular characteristics
• Liquid biopsy offers a novel, non-invasive testing method to determine the molecular profile and suitability for rechallenge